Evidence map›Paper›PMID 29153851›Full record

ReviewCell chemical biology2018

APOBEC Enzymes as Targets for Virus and Cancer Therapy.

Margaret E Olson, Reuben S Harris, Daniel A Harki

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 165 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Integrating plasma proteome with genome reveals novel protein biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Margaret E OlsonDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA.
Reuben S HarrisHoward Hughes Medical Institute, University of Minnesota, Minneapolis, MN 55455, USA; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Daniel A HarkiDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USA; Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: daharki@umn.edu.
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

APOBEC3 Proteins in HIV RestrictionR37AI064046 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HARRIS, REUBEN S · 2015 to 2024
$4.2M
APOBEC3 STRUCTURAL STUDIESR01GM118000 · NIGMS · UNIVERSITY OF MINNESOTA · PI AIHARA, HIDEKI, HARRIS, REUBEN S · 2016 to 2019
$2.2M
Chemical Interrogation of Human DNA Cytosine DeaminasesR01GM110129 · NIGMS · UNIVERSITY OF MINNESOTA · PI HARKI, DANIEL A · 2015 to 2019
$1.8M
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESISR21CA206309 · NCI · UNIVERSITY OF MINNESOTA · PI HARRIS, REUBEN S · 2016 to 2017
$401k
Chemical Probes of Endogenous Mutation: Small Molecule APOBEC3B InhibitorsF31CA183246 · NCI · UNIVERSITY OF MINNESOTA · PI OLSON, MARGARET EMILY · 2014 to 2014
$28k
Howard Hughes Medical InstituteNCI NIH HHS F31 CA183246NCI NIH HHS R21 CA206309NIAID NIH HHS R37 AI064046NIGMS NIH HHS R01 GM110129NIGMS NIH HHS R01 GM118000
6 · The paper itself

Abstract

Human DNA cytosine-to-uracil deaminases catalyze mutations in both pathogen and cellular genomes. APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H restrict human immunodeficiency virus 1 (HIV-1) infection in cells deficient in the viral infectivity factor (Vif), and have the potential to catalyze sublethal levels of mutation in viral genomes in Vif-proficient cells. At least two APOBEC3 enzymes, and in particular APOBEC3B, are sources of somatic mutagenesis in cancer cells that drive tumor evolution and may manifest clinically as recurrence, metastasis, and/or therapy resistance. Consequently, APOBEC3 enzymes are tantalizing targets for developing chemical probes and therapeutic molecules to harness mutational processes in human disease. This review highlights recent efforts to chemically manipulate APOBEC3 activities.

Indexed as

Anti-HIV AgentsAntineoplastic AgentsAPOBEC DeaminasesEnzyme InhibitorsHIV-1HumansNeoplasmsAnti-HIV AgentsAntineoplastic AgentsAPOBEC DeaminasesEnzyme InhibitorsAPOBECcancerchemical probescytosine-to-uracilmutationvirus

Identifiers

PMID29153851
PMCPMC5775913
OpenAlexW2770122068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.